DURHAM, N.C. & SEATTLE--January 12, 2025--Leading epigenome editing company Tune Therapeutics (Tune) today announced the completion of over $175M in financing led by New Enterprise Associates, Yosemite, Regeneron Ventures and...
MethylGene and Pharmion report preliminary clinical data at the 2007 AACR-NCI-EORTC International Conference
News | 10. 24. 2007
MethylGene Inc. (TSX:MYG) and Pharmion Corporation (NASDAQ:PHRM) today reported preliminary clinical data from the Companies' MGCD0103 Phase I/II combination trial with Gemzar® (Trial 006). The data were presented in a poster session at the 2007 AACR-NCI- EORTC International Conference on Molecular Targets and Cancer Therapeutics in San Francisco on October 24th, 2007.
